Galmed Financial Statements From 2010 to 2026

GLMD Stock  USD 0.75  0.04  5.06%   
Galmed Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Galmed Pharmaceuticals' valuation are provided below:
Market Capitalization
4.1 M
Earnings Share
(3.44)
There are over one hundred nineteen available fundamental trends for Galmed Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Galmed Pharmaceuticals' regular performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. As of January 2, 2026, Market Cap is expected to decline to about 3.2 M. The current year's Enterprise Value is expected to grow to about (1.8 M)

Galmed Pharmaceuticals Total Revenue

2.04 Million

Check Galmed Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Galmed Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 95.4 K, Interest Expense of 16.4 K or Selling General Administrative of 4.3 M, as well as many indicators such as Price To Sales Ratio of 1.1 K, Dividend Yield of 0.0 or PTB Ratio of 0.17. Galmed financial statements analysis is a perfect complement when working with Galmed Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Galmed Stock
Check out the analysis of Galmed Pharmaceuticals Correlation against competitors.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.

Galmed Pharmaceuticals Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares OutstandingM837.7 K1.4 M
Slightly volatile
Total Assets34.1 M21.3 M27 M
Slightly volatile
Short and Long Term Debt Total35.1 K36.9 K508.2 K
Slightly volatile
Other Current Liabilities694.4 K994.8 K593 K
Slightly volatile
Total Current Liabilities3.9 M2.5 M3.1 M
Slightly volatile
Other Liabilities485.1 K915.4 K634.2 K
Slightly volatile
Accounts Payable1.4 M1.5 M2.3 M
Slightly volatile
Cash6.4 M4.2 M6.8 M
Very volatile
Non Current Assets Total2.9 M2.7 M1.1 M
Slightly volatile
Long Term Debt1.5 M1.6 M1.8 M
Slightly volatile
Cash And Short Term Investments32.4 M17.6 M25.6 M
Slightly volatile
Net Receivables131.4 K240.3 K114.4 K
Slightly volatile
Common Stock Total Equity41.4 K66.7 K40.8 K
Slightly volatile
Liabilities And Stockholders Equity34.1 M21.3 M27 M
Slightly volatile
Other Current Assets449.9 K671.6 K379.2 K
Slightly volatile
Other Stockholder Equity143.2 M248.9 M123.5 M
Slightly volatile
Total Liabilities4.3 M2.5 M3.7 M
Pretty Stable
Property Plant And Equipment Gross719.7 K1.3 M620.8 K
Slightly volatile
Total Current Assets33 M18.5 M26.1 M
Slightly volatile
Short Term Debt85.1 K47.1 K116.7 K
Very volatile
Common Stock896 K853.3 K187.8 K
Slightly volatile
Property Plant Equipment519.1 K387.6 K393.9 K
Slightly volatile
Short Term Investments11.7 M12.3 M19.8 M
Pretty Stable
Capital Surpluse129.3 M203.2 M126.4 M
Slightly volatile
Deferred Long Term Liabilities423.2 K476.1 K519.7 K
Slightly volatile
Net Invested Capital29.2 M14.7 M26.3 M
Pretty Stable
Net Working Capital11.9 M12.6 M24.4 M
Very volatile
Capital Stock896 K853.3 K204.6 K
Slightly volatile

Galmed Pharmaceuticals Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization95.4 K95.5 K78.2 K
Pretty Stable
Selling General Administrative4.3 M3.7 M3.5 M
Slightly volatile
Other Operating Expenses6.9 M7.2 M12.9 M
Pretty Stable
Research Development3.3 M3.4 M9.3 M
Pretty Stable
Interest Income726.1 K578.5 K438.6 K
Slightly volatile
Reconciled Depreciation89.4 K74.7 K160.7 K
Slightly volatile
Selling And Marketing Expenses34.2 K36 K171.2 K
Slightly volatile

Galmed Pharmaceuticals Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation454 K477.9 K1.6 M
Pretty Stable
Begin Period Cash Flow3.3 M3.4 M6.3 M
Pretty Stable
Depreciation95.4 K95.5 K78.2 K
Pretty Stable
Total Cash From Financing Activities11.4 M7.9 M12.5 M
Very volatile
End Period Cash Flow6.5 M4.3 M6.9 M
Very volatile
Sale Purchase Of Stock156.2 K164.4 KM
Pretty Stable
Net Borrowings1.5 M1.6 M1.8 M
Slightly volatile
Change To Netincome2.2 M1.6 M4.5 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio1.1 K838914
Slightly volatile
Days Sales Outstanding9.9810.599.4324
Slightly volatile
Stock Based Compensation To Revenue0.961.011.9871
Slightly volatile
Capex To Depreciation0.120.136.7019
Slightly volatile
EV To Sales1.1 K825904
Slightly volatile
Days Of Inventory On Hand9511.1 K1.2 K
Slightly volatile
Payables Turnover0.060.05710.0224
Slightly volatile
Sales General And Administrative To Revenue4.52.514.2293
Slightly volatile
Research And Ddevelopement To Revenue4.464.6915.3241
Slightly volatile
Capex To Revenue0.02660.03970.0382
Pretty Stable
Cash Per Share23.8814.8225.3522
Slightly volatile
Days Payables Outstanding6.3 K6.6 K31.7 K
Very volatile
Income Quality0.670.70.8374
Very volatile
Current Ratio10.328.538.4481
Pretty Stable
Receivables Turnover37.7635.9623.8186
Slightly volatile
Capex Per Share0.00260.00270.1069
Slightly volatile
Revenue Per Share0.961.521.1701
Slightly volatile
Interest Debt Per Share0.01760.01851.0483
Slightly volatile
Debt To Assets0.00270.00280.4303
Slightly volatile
Operating Cycle1.1 K1.1 K644
Slightly volatile
Days Of Payables Outstanding6.3 K6.6 K31.7 K
Very volatile
Quick Ratio10.788.538.7944
Very volatile
Net Income Per E B T1.091.21.0172
Slightly volatile
Cash Ratio3.82.463.1695
Pretty Stable
Days Of Inventory Outstanding9511.1 K1.2 K
Slightly volatile
Days Of Sales Outstanding9.9810.599.4324
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.111.151.0244
Slightly volatile
Fixed Asset Turnover9.939.455.8635
Slightly volatile
Debt Ratio0.00270.00280.4303
Slightly volatile
Price Sales Ratio1.1 K838914
Slightly volatile
Asset Turnover0.03890.02590.028
Pretty Stable

Galmed Pharmaceuticals Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap3.2 M3.4 M735.5 M
Slightly volatile

Galmed Fundamental Market Drivers

Galmed Upcoming Events

3rd of April 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Galmed Pharmaceuticals Financial Statements

Galmed Pharmaceuticals stakeholders use historical fundamental indicators, such as Galmed Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Galmed Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Galmed Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Galmed Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Galmed Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue-153.9 K-146.2 K
Cost Of Revenue74.7 K71 K
Stock Based Compensation To Revenue 1.01  0.96 
Sales General And Administrative To Revenue 2.51  4.50 
Research And Ddevelopement To Revenue 4.69  4.46 
Capex To Revenue 0.04  0.03 
Revenue Per Share 1.52  0.96 
Ebit Per Revenue(4.73)(4.97)

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Galmed Pharmaceuticals is a strong investment it is important to analyze Galmed Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Galmed Pharmaceuticals' future performance. For an informed investment choice regarding Galmed Stock, refer to the following important reports:
Check out the analysis of Galmed Pharmaceuticals Correlation against competitors.
For information on how to trade Galmed Stock refer to our How to Trade Galmed Stock guide.
You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Galmed Pharmaceuticals. If investors know Galmed will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Galmed Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.44)
Return On Assets
(0.21)
Return On Equity
(0.46)
The market value of Galmed Pharmaceuticals is measured differently than its book value, which is the value of Galmed that is recorded on the company's balance sheet. Investors also form their own opinion of Galmed Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Galmed Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Galmed Pharmaceuticals' market value can be influenced by many factors that don't directly affect Galmed Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Galmed Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Galmed Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Galmed Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.